Regeneron(REGN) GlobeNewswire·2025-06-07 22:30Core Insights - Dupixent has shown a significant efficacy in treating atopic dermatitis in patients with skin of color, achieving a 75% or greater improvement in overall disease severity in over 76% of treated patients [1][5] - The DISCOVER trial results highlight the importance of understanding chronic diseases in underserved populations, particularly in communities of color [1][2] Group 1: Clinical Trial Results - The DISCOVER Phase 4 trial involved 120 patients with atopic dermatitis and skin of color, with 82% being Black [2][5] - At 24 weeks, 76% of patients achieved a ≥75% improvement in overall disease severity (EASI-75), and 53% reported clinically meaningful improvement in itch [5][7] - Patients experienced a 53% reduction in post-inflammatory hyperpigmentation, with scores decreasing from 5.1 (moderate/marked) to 2.4 (mild) [5][6] Group 2: Safety Profile - The safety results from the DISCOVER trial were consistent with Dupixent's known safety profile, with an overall adverse event rate of 42% [3] - Common adverse events included headache (3%), upper respiratory tract infection (2%), and conjunctivitis (3%) [3] Group 3: Disease Characteristics - Atopic dermatitis presents differently in patients with skin of color, often leading to misdiagnosis or underestimation of disease severity [4] - Patients with darker skin tones are more likely to experience severe skin dryness, dyspigmentation, and hardened skin lesions compared to those with lighter skin [4] Group 4: Dupixent Overview - Dupixent is a fully human monoclonal antibody that inhibits IL-4 and IL-13 signaling pathways, addressing type 2 inflammation [8] - It has received regulatory approvals in over 60 countries for various indications, including atopic dermatitis and asthma, with over 1 million patients treated globally [9][11]